The objective of this contract is to adapt the ipda for the measurement of latent HIV-1 for individuals with HIV-1 viral genetic subtype CRF-1_AE.
Ended Definitive Contract Awarded Last action
- Contract number
- 75N93020C00015
- Awardee
-
Accelevir Diagnostics LLC UEI F6SKM7YHCUS7
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $299,975
Award facts
- Opportunity
-
- A solicitation of the national institutes of health (NIH) and the centers for disease control and prevention (CDC) for small business innovation research (sbir) contract proposals Solicitation · SBIRPHS20201 · Posted Jun 21, 2019
- IPDA for High-Priority HIV-1 Subtypes to Enable Global Eradication Trials Award Notice · Posted Jun 16, 2020
- Contract value 100% obligated
- $299,975.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 3 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Baltimore, MD 21202, USA
- Research
- SBIR Program Phase I Action
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $299,975 |
About this award
This federal contract award was issued by the National Institute of Allergy and Infectious Diseases (NIAID), which is part of the U.S. Department of Health and Human Services, to Accelevir Diagnostics LLC, a woman-owned small business. The contract, valued at $299,975.00, is for the company to adapt its Intact Proviral DNA Assay (IPDA) to measure latent HIV-1 for individuals with the CRF-1_AE genetic subtype of the virus. This contract is part of NIAID's Small Business Innovation Research (SBIR) program, which is a set-aside for small businesses to conduct research and development to support the agency's mission. Accelevir Diagnostics has received multiple SBIR awards from NIAID, totaling over $10 million, to develop advanced HIV diagnostic and measurement technologies, including the IPDA, to support global HIV cure and clinical trials.
Quick answers
Who was awarded contract 75N93020C00015?
75N93020C00015 was awarded to Accelevir Diagnostics LLC by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on June 1, 2020.
How much is contract 75N93020C00015 worth?
The government has obligated $299,975 on 75N93020C00015.
Was contract 75N93020C00015 competed?
The extent of competition for 75N93020C00015 was full and open competition after exclusion of sources. The government received 3 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award